502 related articles for article (PubMed ID: 17785617)
1. Fingolimod: a novel immunosuppressant for multiple sclerosis.
Brown BA; Kantesaria PP; McDevitt LM
Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
[TBL] [Abstract][Full Text] [Related]
2. Fingolimod for relapsing multiple sclerosis: an update.
Horga A; Castilló J; Montalban X
Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
[TBL] [Abstract][Full Text] [Related]
3. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
[TBL] [Abstract][Full Text] [Related]
4. FTY720 (fingolimod) in renal transplantation.
Budde K; Schütz M; Glander P; Peters H; Waiser J; Liefeldt L; Neumayer HH; Böhler T
Clin Transplant; 2006; 20 Suppl 17():17-24. PubMed ID: 17100697
[TBL] [Abstract][Full Text] [Related]
5. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
6. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
[TBL] [Abstract][Full Text] [Related]
7. FTY720 (fingolimod) for relapsing multiple sclerosis.
Horga A; Montalban X
Expert Rev Neurother; 2008 May; 8(5):699-714. PubMed ID: 18457527
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod for the treatment of relapsing multiple sclerosis.
Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
[TBL] [Abstract][Full Text] [Related]
9. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480
[TBL] [Abstract][Full Text] [Related]
10. [Fingolimod - a new immunomodulator].
Friedrich FW; Eschenhagen T
Dtsch Med Wochenschr; 2009 Oct; 134(42):2127-31. PubMed ID: 19809964
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod therapy for multiple sclerosis.
Willis MA; Cohen JA
Semin Neurol; 2013 Feb; 33(1):37-44. PubMed ID: 23709211
[TBL] [Abstract][Full Text] [Related]
12. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
13. Delayed fingolimod-associated asystole.
Espinosa PS; Berger JR
Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609
[TBL] [Abstract][Full Text] [Related]
14. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B; Ross AP; Tobias K
Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L;
Mult Scler; 2010 Feb; 16(2):197-207. PubMed ID: 20028707
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
Massberg S; von Andrian UH
N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
[No Abstract] [Full Text] [Related]
18. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
Széplaki G; Merkely B
Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171
[TBL] [Abstract][Full Text] [Related]
19. [Fingolimod treatment in multiple sclerosis].
Tanaka M
Nihon Rinsho; 2014 Nov; 72(11):2010-4. PubMed ID: 25518386
[TBL] [Abstract][Full Text] [Related]
20. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
